SCHEMBL4840415

SCHEMBL4840415

CCN(C(=O)C(CC(=O)OC(C)(C)C)C(CCc1ccccc1)C(=O)O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 2/20 0.41
CTSK P43235 3/20 0.39
CTSS P25774 2/20 0.39
MMP12 P39900 5/20 0.39
MMP13 P45452 2/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP14 P50281 1/20 0.39
MME P08473 2/20 0.36
PTGES O14684 1/20 0.36
ALOX5 P09917 1/20 0.36
ACE P12821 1/20 0.35
CPA1 P15085 1/20 0.35
ACE2 Q9BYF1 1/20 0.35
GPR88 Q9GZN0 1/20 0.35
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PRSS1 P07477 1/20 0.34
CTSG P08311 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4840702 0.86 MMP12 (0.50) MLYCDMMP12MMP13MMP2MMP9
SCHEMBL4839575 0.86 CTSK (0.38) MLYCDCTSKCTSSMMP12MMP13
SCHEMBL4841242 0.78 ALDH1A1 (0.38) MLYCDCTSKCTSSMMP12PTGES
SCHEMBL4834721 0.76 MMP12 (0.46) MLYCDMMP12MMP13MMP2MMP9
SCHEMBL4841055 0.76 SMN1; SMN2 (0.41) GPR88ALDH1A1SMN1; SMN2
SCHEMBL5613391 0.74 MMP12 (0.65) CTSKCTSSMMP12MMP13MMP2
SCHEMBL4838598 0.74 CA2 (0.35) PTGESALOX5GPR88ALDH1A1HPGD
SCHEMBL6252470 0.74 MMP12 (0.42) MLYCDMMP12MMP13MMP2MMP9
SCHEMBL4840439 0.74 CTSK (0.44) CTSKCTSSMMP9SMN1; SMN2PRSS1
SCHEMBL4838569 0.72 KIF11 (0.36) MLYCDPTGESALOX5GPR88ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD MLYCD 195/4885CTSK 2373/4885CTSS 1630/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD MLYCD 190/4885CTSK 2501/4885CTSS 1756/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH MLYCD 191/4885CTSK 2579/4885CTSS 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.